Alectinib Hydrochloride is a potent, second-generation anaplastic lymphoma kinase (ALK) inhibitor designed for the treatment of ALK-positive non-small cell lung cancer, particularly cases involving brain… Read more
Alectinib Hydrochloride is a potent, second-generation anaplastic lymphoma kinase (ALK) inhibitor designed for the treatment of ALK-positive non-small cell lung cancer, particularly cases involving brain metastases. This small-molecule oral agent functions by selectively targeting ALK receptor tyrosine kinase to inhibit tumor cell proliferation and survival. The accompanying range of high-quality reference standards, including the active pharmaceutical ingredient, critical degradation products like sulfonic acid derivatives, structural analogues, and stable isotope-labelled compounds, is essential for robust pharmaceutical analysis. These materials enable precise impurity profiling, method validation, and rigorous quality control within laboratory settings. By utilizing these characterized standards, researchers and analysts can accurately quantify impurities, monitor degradation pathways, and support the developmental stability testing necessary to ensure the therapeutic efficacy and safety of the final formulation during the complex drug manufacturing process.
![Chemical structure of 8-bromo-9-methoxy-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1256581-49-3-8-bromo-9-methoxy-66-dimethyl-11-oxo-611-dihydro-5H-benzobcarbazole-3-carbonitrile.png&w=3840&q=75)